WO2000071171A3 - Ligands sigma-1 utiles pour determiner l'etat de proliferation de cellules cancereuses - Google Patents

Ligands sigma-1 utiles pour determiner l'etat de proliferation de cellules cancereuses Download PDF

Info

Publication number
WO2000071171A3
WO2000071171A3 PCT/US2000/013834 US0013834W WO0071171A3 WO 2000071171 A3 WO2000071171 A3 WO 2000071171A3 US 0013834 W US0013834 W US 0013834W WO 0071171 A3 WO0071171 A3 WO 0071171A3
Authority
WO
WIPO (PCT)
Prior art keywords
sigma
ligands
proliferative status
determining
determining carcinoma
Prior art date
Application number
PCT/US2000/013834
Other languages
English (en)
Other versions
WO2000071171A2 (fr
Inventor
Robert H Mach
Yunsheng Huang
Steven R Childers
Kenneth T Wheeler
Original Assignee
Univ Wake Forest
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wake Forest filed Critical Univ Wake Forest
Priority to AU50324/00A priority Critical patent/AU5032400A/en
Publication of WO2000071171A2 publication Critical patent/WO2000071171A2/fr
Publication of WO2000071171A3 publication Critical patent/WO2000071171A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne une méthode permettant de déterminer l'état de prolifération de cellules cancéreuses exprimant des récepteurs sigma-1, ainsi que des composés marqués de façon à pouvoir être identifiés et des compositions pharmaceutiques utiles pour mettre en oeuvre de telles méthodes.
PCT/US2000/013834 1999-05-21 2000-05-19 Ligands sigma-1 utiles pour determiner l'etat de proliferation de cellules cancereuses WO2000071171A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU50324/00A AU5032400A (en) 1999-05-21 2000-05-19 Sigma-1 ligands useful for determining the proliferative status of cancer cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13527499P 1999-05-21 1999-05-21
US60/135,274 1999-05-21

Publications (2)

Publication Number Publication Date
WO2000071171A2 WO2000071171A2 (fr) 2000-11-30
WO2000071171A3 true WO2000071171A3 (fr) 2001-06-28

Family

ID=22467347

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/013834 WO2000071171A2 (fr) 1999-05-21 2000-05-19 Ligands sigma-1 utiles pour determiner l'etat de proliferation de cellules cancereuses

Country Status (2)

Country Link
AU (1) AU5032400A (fr)
WO (1) WO2000071171A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1603899B1 (fr) 2003-03-06 2009-08-26 Glaxo Group Limited Derives d'uree heterocycliques pour le traitement de la douleur
WO2004078744A2 (fr) 2003-03-07 2004-09-16 Glaxo Group Limited Derives d'uree
GB0305426D0 (en) * 2003-03-08 2003-04-16 Glaxo Group Ltd Novel compounds
EP3148518B1 (fr) * 2014-05-30 2022-11-30 Sphaera Pharma Pvt. Ltd. Nouveaux composés utilisés comme agents anti-tuberculeux
UY36391A (es) * 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2008439A6 (es) * 1988-03-30 1989-07-16 Espanola Prod Quimicos Procedimiento de preparacion de nuevos derivados de 4-piperidinalcanaminas.
US5492918A (en) * 1993-06-08 1996-02-20 Bayer Aktiengesellschaft Use of substituted chromans, some of which are known, as medicaments, new active compounds and processes for their preparation
WO1996020928A1 (fr) * 1995-01-03 1996-07-11 Australian Nuclear Science & Technology Organisation Ligands de recepteurs sigma a base de piperidine
US5630996A (en) * 1992-06-09 1997-05-20 Neorx Corporation Two-step pretargeting methods using improved biotin-active agent conjugates

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2008439A6 (es) * 1988-03-30 1989-07-16 Espanola Prod Quimicos Procedimiento de preparacion de nuevos derivados de 4-piperidinalcanaminas.
US5630996A (en) * 1992-06-09 1997-05-20 Neorx Corporation Two-step pretargeting methods using improved biotin-active agent conjugates
US5492918A (en) * 1993-06-08 1996-02-20 Bayer Aktiengesellschaft Use of substituted chromans, some of which are known, as medicaments, new active compounds and processes for their preparation
WO1996020928A1 (fr) * 1995-01-03 1996-07-11 Australian Nuclear Science & Technology Organisation Ligands de recepteurs sigma a base de piperidine

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CARLING ET. AL.: "1-(3-Cyanobenzylpiperidin-4-yl)-5-methyl-4-phenyl-1,3-dihydroimidazol-2-one", J. MED. CHEM., vol. 42, no. 14, July 1999 (1999-07-01), pages 2707 - 15, XP002154247 *
CAYRE ET AL.: "Comparitive 99mTc-Sestamibi and 3H-Daunomycin uptake in human carcinoma cells: relation to the MDR phenotype and effects of reversing agents", J. NUCL. MED., vol. 40, no. 4, April 1999 (1999-04-01), pages 673 - 75, XP002154248 *
HUANG ET AL.: "Synthesis and quantitative structure-activity relationships of N-(1-benzylpiperidin-4-yl)phenylacetamides and related analogues as potent and selective sigma1 receptors", J. MED. CHEM., vol. 41, 1998, pages 2361 - 70, XP002154246 *
MEEGALLA ET AL.: "First example of a 99mTc Complex as a dopamine transporter imaging agent", J. AM. CHEM. SOC., vol. 117, 1995, pages 11037 - 11038, XP002154249 *

Also Published As

Publication number Publication date
AU5032400A (en) 2000-12-12
WO2000071171A2 (fr) 2000-11-30

Similar Documents

Publication Publication Date Title
EP1226823A3 (fr) Méthode de traitement de certains cancers avec un agoniste/antagoniste des estrogènes
WO1999003822A8 (fr) Ligands des recepteurs bicycliques metabotropiques du glutamate
AU6790000A (en) Improved fill material for dual damascene processes
AU5993399A (en) Gps location for mobile phones using the internet
WO2004096144A3 (fr) Compositions et methodes d'induction de recepteurs opoides
MXPA03007892A (es) Aditivo para suspension deshidratable.
HK1031399A1 (en) Process for synthesizing cox-2 inhibitors.
GC0000129A (en) Method for annular sealing.
NO20025016L (no) Korrosjonsbeskyttet koaksialkabel, fremgangsmåte for fremstilling av sammeog korrosjonsinhiberende sammensetning
AU2003264068A1 (en) Compositions and methods for treating cancer using maytansinoid cd44 antibody immonoconjugates and chemotherapeutic agents
WO2003057163A3 (fr) Preparation d'immunoconjugues
ZA200007090B (en) Coated PCBN cutting tools.
WO2001016133A3 (fr) Composes de 6-trifluoromethyl-9-pyrido[3,2-g]quinoline 8-substitues utilises comme modulateurs de recepteurs androgenes
WO2003048301A3 (fr) Anticorps anti-hla-dr et leurs methodes d'utilisation
HK1045693A1 (en) Bicyclic compounds composition and method for stabilizing the same.
AU2002348503A1 (en) Quinuclidine-substituted heteroaromatic compounds as ligands at nicotinic acetylcholine receptors
ZA993230B (en) R.B. Jun method for surface mining.
WO2005111076A8 (fr) Nectine 4 (n4) utilisee comme marqueur du pronostic du cancer
AU2002305117A1 (en) Improved apparatus, methods and compositions for biotechnical separations
WO2002012224A3 (fr) Composes bicycliques
AU1514200A (en) Apparatus for directional drilling
AU2003213960A1 (en) Methods for detecting ovarian cancer
ZA200309514B (en) Pyrido-pyrido-pyrrolo pyrrolo-indole and pyrido-pyrrolo pyrrolo carbazole derivatives, method for the production thereof and pharmaceutical compositions containing said derivatives.
WO2000071171A3 (fr) Ligands sigma-1 utiles pour determiner l'etat de proliferation de cellules cancereuses
AU2002353910A1 (en) Process for the preparation of aniline-derived thyroid receptor ligands

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP